Cantor Fitzgerald analyst William Tanner reiterates his belief that TherapeuticsMD's TX-001 could be a "far-bigger" drug than the company's TX-004. Consistent with previous guidance, TherapeuticsMD filed yesterday the new drug application for TX-001, the estrogen plus progesterone hormone replacement therapy for treating vasomotor symptoms associated with menopause in women, Tanner tells investors in a research note. If approved, TX-001 could enter a vasomotor symptoms market "characterized by the absence of FDA-approved therapies," the analyst contends. He believes investors may be overlooking TX-001 "with all the fireworks over TX-004 in the past six months." Tanner reiterates an Overweight rating on TherapeuticsMD with a $28 price target. The stock in premarket trading is up 4% to $6.19.